Abiopharma

New Form 8-K - Imunon, Inc. Filed: 2025-08-05 AccNo: 0001493152-25-011597 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Curis Provides Second Quarter 2025 Business Update

SenesTech Announces Warrant Exercise for $6.3 Million in Gross Proceeds

Tharimmune Inc Notification (THAR)

New Form 8-K - CORE MOLDING TECHNOLOGIES INC Filed: 2025-08-05 AccNo: 0001026655-25-000066 Size: 486 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

electroCore Appoints James C. Theofilos to the Board of Directors

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Bionano Announces Upgrades to its Software and Compute Platforms to Make Analysis of OGM, Microarray and NGS Data Easier, Faster and More Accurate

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Nuvation Bio Inc. - Nuvation Bio To Present New Data onIBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

New Form 10-Q - MESA LABORATORIES INC /CO/ Filed: 2025-08-05 AccNo: 0001437749-25-024715 Size: 6 MB